ResMed Inc. (NYSE: RMD) reported disappointing results from a Phase III trial
of its sleep apnea treatment Adaptive Servo-Ventilation therapy sending the stock price plummeting $9.89 to close at $55.48.
Disappointing trial results for ResMed
May 13, 2015 at 17:38 PM EDT
